{"entity":{"id":"naporafenib","kind":"drug","name":"Naporafenib","aka":[],"tldr":"Naporafenib is an experimental small-molecule drug from Erasca in phase 3 trials for melanoma, with its target not yet stated publicly.","summary":"Naporafenib (ERAS-254, LXH254) is a small-molecule drug developed by Erasca. The sponsor describes its target as RAF (pan-RAF), which OnCo does not yet have a target page for. The sponsor states: An experimental pan-RAF inhibitor blocking RAF kinase signalling in the MAPK pathway, studied in combination with the MEK inhibitor trametinib in NRAS-mutant melanoma. ClinicalTrials.gov describes the intervention as: Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)), in melanoma. The largest, NCT06346067, plans to enrol 78 participants (actual) with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Naporafenib","url":"https://clinicaltrials.gov/search?intr=ERAS-254"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["erasca"],"institutions":[],"pathways":[],"terms":[],"trials":["seacraft-2","nct04417621"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"ERAS-254, LXH254","modality":"small molecule","mechanism":"An experimental pan-RAF inhibitor blocking RAF kinase signalling in the MAPK pathway, studied in combination with the MEK inhibitor trametinib in NRAS-mutant melanoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/naporafenib/","neighbours":{"cancer":[{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/"}],"company":[{"id":"erasca","kind":"company","name":"Erasca","route":"/companies/erasca/"}],"trial":[{"id":"seacraft-2","kind":"trial","name":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","route":"/trials/seacraft-2/"},{"id":"nct04417621","kind":"trial","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","route":"/trials/nct04417621/"}],"target":[{"id":"nras","kind":"target","name":"NRAS","route":"/targets/nras/"}]}}